Skip to content
★ Sign in to follow
BP

Bacil Pharma Stock: price and insider trades · India

IN·Mcap ₹307.4M

No insider purchase over the last 90 days. The latest, by Niraj Rajnikant Shah, was filed 16 Jul 2026.

Bacil Pharma: what insiders have been doing

Bacil Pharma is a listed company. Its directors and officers file their transactions with SEBI (PIT + SAST). In the past year (18 October 2025 to 18 October 2026), 5 filings came from 5 insiders.

Purchases and sales both appear in the filings: 1 purchase (1 insider) and 4 sales (4 insiders). The totals do not cover 5 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.

The last insider purchase was made public on 16 July 2026, 117 days ago. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. Until a filing is published, the market cannot know about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

For context, the typical company on the same exchange (median of 1,985 companies) published 4 filings over the same period, against 5 filings here. Since 2026, the database holds 1 purchase and 4 sales by insiders of the company.

These figures are compiled from regulatory filings published by SEBI (PIT + SAST). They describe what insiders did and are not a recommendation.

Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
n/a
4 ops. · all time

Who traded when

BuySale
Manubhai Amrutlal Shah1 sale
Manubhai Shah1 sale
Nikita Hiren Patel1 sale
Nikita Patel1 sale
Niraj Rajnikant Shah1 buy

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹21.42
Analyst consensus
·
Income statement
EBITDA₹9.9M
Net income₹15.6M0.0% margin
Valuation
PER (trailing)30.6x
P/Book1.2x
Beta0.15
Balance sheet & cash
Market cap₹307.4M
Free Cash Flow₹7.1M
Profitability & ownership
ROE6.2%
ROA-0.6%
% insiders63.7%
% institutions0.0%
Last declaration on 16 July 2026
Declarations5 total
  • ▼
    OtherExecutives
    0SEBI
    394,893 shares-MarketSEBI:10dc328e6466141cc2bc8697c53ddcefa2610201
  • ▼
    OtherExecutives
    0SEBI
    1,019,052 shares-MarketSEBI:b42a729b6bbd3ef1ad810f73dad76a828b065633
  • ▲
    OtherExecutives
    0SEBI
    925,000 shares-MarketSEBI:1419804ee561a46934bb7f3edeec51ef82157079
    Canonical exit: 14 Oct 2026 (T+90)
  • ▼
    OtherExecutives
    0SEBI
    326,104 shares-MarketSEBI:a3051dd4aaa69fd0ebccf437f3a5da249950a913
  • ▼
    OtherExecutives
    0SEBI
    800,000 shares-MarketSEBI:e07ace6c5dc5d283f4cf2c5325ccf6d8ada0a25e

5 of 5 declarations

About Bacil Pharma

Bacil Pharma is a pharmaceutical company operating in the XBOM market. It focuses on the development and commercialization of innovative pharmaceutical products.